The woman, who had been treated years earlier for low-grade B-cell non-Hodgkin lymphoma with a rituximab-based regimen, arrived at the hospital with dangerously low blood pressure — 86/58 — and severe swelling in both legs. Lab tests revealed massive protein leakage into her urine, a condition known as nephrotic-range proteinuria, along with acute kidney injury. Her creatinine, a marker of kidney function, was elevated at 1.8 mg/dL, and her urine protein-to-creatinine ratio exceeded 10 g/g, a level indicating profound kidney damage. She was diagnosed with nephrotic syndrome of uncertain origin and scheduled for a renal biopsy to find the cause.

What the biopsy revealed was light chain (AL) amyloidosis — a rare protein misfolding disorder in which abnormal immunoglobulin light chains, produced by a clonal population of plasma cells or B cells, fold incorrectly and aggregate into insoluble fibrils that deposit in organs, disrupting their structure and function. In this patient, the amyloid deposits were composed of lambda light chains and had infiltrated the glomeruli, interstitium, arteries, and arterioles of her kidneys. Light microscopy showed 52% global glomerulosclerosis, moderate interstitial fibrosis, and moderate acute tubular injury — evidence that the deposits had already caused substantial, though not yet irreversible, damage.

AL amyloidosis is uncommon, with an estimated incidence of 9 to 14 cases per million person-years in the United States. It typically arises from plasma cell dyscrasias such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS). But in rare instances, it can originate from B-cell lymphomas — a distinctly less prevalent pathogenic subtype that reflects an alternative lymphoid origin of the misfolded light chains. The clinical consequences depend on where the amyloid accumulates: in the heart, it causes restrictive cardiomyopathy; in the kidneys, it produces nephrotic-range proteinuria and progressive renal failure; and systemically, it can cause fatigue, hypotension, and unintentional weight loss.

To identify the source of the amyloid, the team performed a bone marrow biopsy. The results were striking: low-grade B-cell non-Hodgkin lymphoma had infiltrated 85% of the marrow. Immunophenotyping revealed a lambda-restricted clonal B-cell population that was positive for CD20 — a surface marker targeted by rituximab — and negative for CD5, CD10, and CD11c. The immunophenotypic profile raised the possibility of lymphoplasmacytic lymphoma or Waldenström macroglobulinemia, but MYD88 L265P mutation testing was not performed, leaving the precise subtype unresolved. PET imaging confirmed lymphomatous involvement without additional abnormal uptake or lymphadenopathy.

The connection between the two diagnoses was an IgM monoclonal lambda gammopathy detected on serum immunofixation, along with mildly elevated serum lambda free light chains and a decreased kappa-to-lambda ratio of 0.11. These findings indicated that the lymphoma cells were producing the very light chains that were misfolding and depositing as amyloid in her kidneys. The patient was also found to have a positive hepatitis C antibody, though HCV RNA was undetectable and cryoglobulins were absent, making an infectious cause of her kidney disease unlikely.

Treatment was initiated with rituximab and bendamustine, a combination targeting the underlying clonal B-cell disorder driving the amyloid production. The patient tolerated therapy well, and within four weeks her creatinine had improved to 1.15 mg/dL, a sign of recovering kidney function. Her proteinuria also decreased, though it remained elevated at 7.9 g/g. She was simultaneously treated for adrenal insufficiency with hydrocortisone and fludrocortisone, and she reported significant improvement in her peripheral edema.

The case, published in Frontiers in Nephrology, highlights a diagnostic challenge that nephrologists and hematologists rarely encounter. AL amyloidosis is attributed to non-Hodgkin lymphoma in only 1% to 4% of cases, and the overlap in symptoms — fatigue, edema, renal dysfunction — makes it easy to miss. Moreover, nephrotic syndrome in patients with lymphoma has a broad differential diagnosis, including minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, light-chain deposition disease, cast nephropathy, cryoglobulinemic glomerulonephritis, and immune complex membranoproliferative glomerulonephritis. Distinguishing among these entities requires careful integration of clinical features, serologic testing, complement levels, and definitive renal biopsy findings, because treatment differs significantly depending on the underlying pathology.

Prognosis in AL amyloidosis is primarily determined by the extent of organ involvement and disease stage. Cardiac involvement is the most significant predictor of poor outcomes, with heart failure accounting for approximately 50% of amyloidosis-related deaths. Renal failure and infection each contribute roughly 15% of mortality. In untreated patients, progression to dialysis-dependent renal failure occurs in an estimated 60% to 75% within three years. Earlier studies reported median survival as low as six months, though advances in immunomodulatory therapies and earlier diagnosis have substantially improved outcomes.

The authors acknowledge several limitations, including the absence of definitive amyloid typing by laser microdissection with mass spectrometry and the lack of MYD88 L265P mutation testing, which precluded definitive subclassification of the lymphoma. The relatively short follow-up also limits assessment of long-term remission and renal recovery. Nevertheless, the case adds to a limited body of literature on renal AL amyloidosis associated with low-grade B-cell non-Hodgkin lymphoma and reinforces a critical clinical message: persistent nephrotic-range proteinuria in a patient with B-cell lymphoma — particularly when accompanied by IgM lambda monoclonal gammopathy — should prompt urgent evaluation for amyloidosis with renal biopsy and hematologic assessment, because early clone-directed therapy can alter the trajectory of both diseases.

Subject of Research: Renal light chain amyloidosis secondary to low-grade B-cell non-Hodgkin lymphoma

Article Title: Case Report: Light chain amyloidosis in a patient with low-grade B-cell lymphoma

Article References: Case Report: Light chain amyloidosis in a patient with low-grade B-cell lymphoma. (n.d.). https://doi.org/10.3389/fneph.2026.1959759

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1959759

Keywords: AL amyloidosis, light chain amyloidosis, non-Hodgkin lymphoma, renal amyloidosis, nephrotic syndrome, IgM monoclonal gammopathy, rituximab, bendamustine, kidney biopsy, B-cell lymphoma, proteinuria, amyloid fibrils

CAR T-cell therapy is one of the most significant advances in cancer medicine of the past decade. The process begins with the collection of T cells, the immune system’s primary cancer-killing soldiers, from a patient’s own blood. In the laboratory, those cells are genetically modified to express a chimeric antigen receptor, a synthetic molecule that allows the T cell to recognize a specific protein on the surface of cancer cells. Once infused back into the patient, the engineered cells multiply and launch a targeted assault on the tumor. The approach has produced high rates of remission in B-cell blood cancers, a category that accounts for roughly half of all blood cancers and includes lymphomas and certain leukemias.

Despite that success, a major weakness has limited the durability of the treatment. Many patients relapse after CAR T-cell therapy, often within the first year, leaving them with few remaining treatment options. One reason is that the therapy usually targets a single protein, CD19, which plays a central role in B-cell blood cancers. Cancer cells can survive the initial attack by losing or reducing expression of that single target, a phenomenon known as antigen escape. Building on earlier animal studies conducted at other institutions, the Ohio State team designed a therapy that targets three proteins at once: CD19, CD20 and CD22. By forcing the cancer to evade three distinct targets simultaneously, the trispecific construct is intended to make escape far more difficult.

The second innovation in the trial was the use of OX40, an immune costimulatory protein, to strengthen the activity of the engineered cells. According to Sumithira Vasu, MD, professor of hematology and a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, who served as the study’s first and corresponding author, this was the first time a CAR T-cell clinical trial used OX40 to enhance the process and improve tumor death. Costimulatory signals such as OX40 act like an accelerator for T cells, promoting their expansion, persistence and killing capacity after they encounter tumor cells. Vasu noted that results from the trial could lead to better therapeutic outcomes for patients who may have limited options after their B-cell blood cancer has returned or their therapy stopped working.

The trial also addressed a practical challenge that has long troubled the field: manufacturing time. Conventional CAR T-cell production can take weeks, during which aggressive cancers may progress and patients may deteriorate. The Ohio State team used a point-of-care manufacturing process that collected, prepared and returned the cells to the patient in just six days. Critically, the cells were infused fresh rather than frozen, a distinction that some researchers believe preserves the potency of the product. Lapo Alinari, MD, PhD, associate professor of hematology and lead senior co-author of the study, said it has been suggested that fresh cell infusions are preferable, and that the team was able to show the feasibility of rapid manufacturing time and infusion of fresh cells.

The clinical results supported that premise. Alinari reported that the rapid, fresh-cell approach produced meaningful clinical activity with minimal side effects in patients with B-cell non-Hodgkin lymphoma, and achieved remission in mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. These are distinct subtypes of B-cell malignancy with different biological behaviors, and achieving remissions across multiple subtypes suggests the trispecific strategy may have broad applicability. Equally important for an early-phase trial, the therapy was well tolerated, with patients experiencing minimal side effects, an encouraging safety signal for a technology that combines three tumor-targeting domains with an additional immune-boosting element.

Eighteen patients were enrolled in the study, with a median age of 64. Sixteen of them were treated with the OX40-enhanced CAR T-cell product. The patient population reflected the difficult reality of relapsed disease: all enrolled patients had previously received a median of three different types of therapy before receiving the enhanced cell therapy. In other words, these were heavily pretreated individuals whose cancers had already resisted multiple standard approaches, the very group in which new therapies are hardest to evaluate and for whom the unmet need is greatest.

The study was published in Blood Cancer Discovery, a peer-reviewed journal of the American Association for Cancer Research, with the article titled Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22. The research involved a broad team of investigators from Ohio State and Nationwide Children’s Hospital, reflecting the multidisciplinary effort required to move an engineered cell therapy from the laboratory bench to the bedside, including cell processing specialists, biostatisticians, and clinicians across hematology and oncology.

Senior co-author Marcos de Lima, MD, professor of hematology at Ohio State, cautioned that while the trial showed encouraging outcomes for patients with B-cell non-Hodgkin lymphoma treated with the enhanced CAR T-cells, more research in larger patient groups is needed. That caveat is standard and appropriate for a phase I study, which is primarily designed to establish safety and feasibility rather than to definitively measure efficacy. Larger trials will be required to confirm the remission rates, characterize the side-effect profile more completely, and determine whether the OX40 enhancement and trispecific targeting translate into longer-lasting remissions than current single-target products.

Nevertheless, the trial represents a notable step in the evolution of cellular immunotherapy. It combines three strategies that researchers have pursued independently, multi-antigen targeting to prevent immune escape, costimulatory enhancement to strengthen T-cell function, and rapid point-of-care manufacturing to deliver fresh cells before the disease can progress, into a single therapeutic platform. If subsequent studies validate these early findings, the approach could expand the reach of CAR T-cell therapy to patients who currently relapse after standard treatment, and the six-day manufacturing timeline could make this sophisticated form of personalized medicine faster and more accessible for the patients who need it most urgently.

Subject of Research: A first-in-human phase I trial of trispecific OX40-enhanced CAR T-cell therapy for relapsed B-cell blood cancers

Article Title: Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers

Article References: Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CAR T-cell therapy, B-cell blood cancers, non-Hodgkin lymphoma, CD19, CD20, CD22, OX40, clinical trial, immunotherapy, cell manufacturing, Ohio State University, Blood Cancer Discovery

The scale of the donation reflects an unusual fundraising model in which corporate giving amplifies grassroots employee participation. This year’s campaign included more than $766,000 in contributions from employees of the Energy Transfer family of partnerships, which the company matched with corporate funds at a rate of 50 percent. Since the effort began in 2014, employees have led fundraising initiatives that have resulted in more than $20 million donated to UT MD Anderson, and the combined total of company support now exceeds $21 million. That longevity matters in biomedical research, where multi-year funding streams allow laboratories to plan experiments, retain specialized staff, and pursue lines of investigation that may take years to bear fruit.

Leadership at Energy Transfer framed the gift as an expression of a shared institutional mission rather than a one-time gesture. Tom Long, co-Chief Executive Officer of Energy Transfer, said the commitment employees have shown to UT MD Anderson over the years reflects a shared belief in the power of innovation to change lives. He noted that the breakthroughs happening at the cancer center, and the hope they bring to patients and their families, reinforce the importance of the collaboration. Such statements underscore a growing trend in which private companies channel philanthropic resources toward translational biomedical science, bridging gaps that conventional grant funding does not always cover.

At MD Anderson, the funds arrive at a moment when pediatric oncology is undergoing a significant transformation. Childhood cancers are, in many respects, distinct diseases from their adult counterparts, driven by different genetic alterations and arising in tissues that are still developing. That biological reality means that treatments designed and tested primarily in adults cannot simply be transplanted into pediatric care without careful adaptation. Researchers in pediatric divisions therefore focus on identifying the molecular vulnerabilities unique to childhood tumors, developing age-appropriate dosing and treatment protocols, and minimizing the long-term side effects that can follow young patients for decades after they are declared cancer free.

Richard Gorlick, M.D., division head and chair of Pediatrics at UT MD Anderson, emphasized the role that sustained private generosity plays in that enterprise. He said that Energy Transfer, Sunoco and USA Compression employees continue to demonstrate an extraordinary commitment to children and families facing cancer, and that their generosity helps researchers pursue new discoveries and translate those advances into better treatments and outcomes for patients across the country. The language of translation is significant: moving a laboratory finding, such as the identification of a drug target or a new biomarker, into a clinically validated therapy requires resources that sit outside the standard cycle of federal research grants, particularly during the early and risky stages of development.

The human dimension of that research pipeline was on display in this year’s campaign through its patient ambassador, Braeden Cochran, whose medical journey illustrates how clinical research can change the trajectory of a young life. Cochran was diagnosed as a college freshman with a rare sub-type of blood cancer known as non-Hodgkin B-cell lymphoma, a disease in which immune cells called B cells grow uncontrollably. He began treatment at UT MD Anderson in 2024, a point he describes as a turning point in his care. Now 21, he has become a public face of the fundraising effort, demonstrating to employee donors the concrete consequences of their contributions.

Cochran’s treatment included participation in an immunotherapy-based clinical trial, an approach that has reshaped the treatment landscape for several blood cancers in recent years. Immunotherapy works differently from conventional chemotherapy: rather than directly poisoning rapidly dividing cells, it recruits or engineers the patient’s own immune system to recognize and attack malignant cells. For patients, this can mean the ability to tolerate comprehensive treatment protocols more effectively, with different and often more manageable side effects than those associated with intensive traditional regimens. Cochran credited the trial with enabling him to better tolerate his full course of treatment, an outcome that reflects the careful design work that goes into matching patients with experimental approaches suited to their disease.

Equally telling is what Cochran said about the environment in which he received care. He recalled that he did not really have the same confidence in his own healing until he came to UT MD Anderson, and that was where things really started to turn around for him. He described the experience of standing in his hospital room and seeing the research buildings on the same campus just outside, noting that it was encouraging to know that work on new treatments was being done all the time. That physical proximity between bedside and laboratory is a defining feature of comprehensive cancer centers, where clinicians and researchers operate in parallel and patient needs can inform research priorities in near real time.

Today, Cochran is cancer free and back in school, an outcome he attributes to the advanced lifesaving treatment options and expert care he received at the institution. Stories of this kind carry weight beyond their emotional resonance. For the thousands of employees who participate in the annual giving campaign, a named ambassador provides a tangible connection between payroll deductions and scientific progress, and for the researchers who depend on philanthropic support, patient outcomes serve as the clearest possible justification for continued investment in early-stage and high-risk science.

The $2.2 million gift thus arrives as both a financial milestone and a case study in how modern cancer research is funded. Federal agencies remain the largest source of basic biomedical research support, but philanthropy increasingly fills critical roles: seeding pilot studies, supporting clinical trials that test novel immunotherapy approaches, funding young investigators, and sustaining the infrastructure that allows discoveries to move from bench to bedside. With more than $21 million contributed since 2014 and this year’s record total, the Energy Transfer family of partnerships has built one of the more enduring corporate-employee philanthropic partnerships in pediatric oncology. For the children and young adults treated at UT MD Anderson, and for the researchers racing to develop the next generation of therapies, the donation represents something more than a number: it is continued momentum for a scientific enterprise whose ultimate measure is measured in patients who, like Cochran, return to their studies and their lives after cancer.

Subject of Research: Philanthropic funding of pediatric cancer research and immunotherapy clinical trials at UT MD Anderson Cancer Center

Article Title: Energy Transfer and Sunoco donate $2.2 million to support pediatric cancer research at UT MD Anderson

Article References: Energy Transfer and Sunoco donate $2.2 million to support pediatric cancer research at UT MD Anderson. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pediatric cancer, MD Anderson, Energy Transfer, Sunoco, philanthropy, immunotherapy, clinical trial, non-Hodgkin lymphoma, employee giving campaign, cancer research funding, pediatric oncology, translational research

Primary thyroid lymphoma is a genuine medical rarity. The thyroid gland is packed with lymphatic tissue, particularly in people with chronic autoimmune inflammation such as Hashimoto’s thyroiditis, and on rare occasions a lymphoma can originate there directly rather than spreading from elsewhere in the body. Diffuse large B-cell lymphoma, or DLBCL, is the most common aggressive subtype of non-Hodgkin lymphoma overall, but when it presents as the first and only site of disease in the thyroid, it belongs to a small subset of so-called primary extranodal lymphomas. Because so few patients exist, no large randomized trials have ever defined a single standard of care. Treatment decisions are instead stitched together from small case series, registry data, and extrapolation from how DLBCL is managed at other anatomical sites. That evidence gap is precisely what the Hamburg team set out to address by pairing their patient’s story with a structured sweep of the published literature.

The clinical picture in 2017 was textbook for the disease in its most dangerous form. The patient’s enlarged thyroid was compressing her airway, explaining the dyspnoea and cough, while involvement of the recurrent laryngeal nerve that runs alongside the gland accounted for her hoarseness. Staging investigations placed her at Ann Arbor stage IE, meaning the lymphoma was confined to a single extranodal organ, and her International Prognostic Index score of 2 indicated intermediate risk. Histopathological analysis classified the tumor as the non-germinal-center B-cell-like, or non-GCB, subtype, a molecular categorization based on the cell of origin that carries prognostic weight in DLBCL generally. Establishing that classification reliably, the authors emphasize in their review, depends on obtaining an adequate tissue sample — ideally a core needle biopsy or a surgical biopsy — because fine-needle aspirates often cannot provide enough architectural and immunophenotypic detail to distinguish DLBCL from other thyroid malignancies or from inflammatory conditions.

First-line therapy followed the established chemoimmunotherapy playbook. The patient received R-CHOP, the workhorse regimen combining the anti-CD20 monoclonal antibody rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, together with prophylactic treatment directed at the central nervous system. Rituximab’s arrival two decades ago transformed outcomes in DLBCL by targeting the CD20 surface protein found on malignant B cells, and the literature review confirms that rituximab-containing chemoimmunotherapy remains the backbone of first-line treatment for primary thyroid DLBCL as well, occasionally supplemented with radiotherapy to the thyroid bed. Surgery, by contrast, played essentially no therapeutic role: across the reviewed literature, operations were largely confined to obtaining diagnostic tissue rather than attempting resection, a notable departure from how many solid thyroid cancers are managed with near-total thyroidectomy.

The initial response was complete remission, and for six years the patient remained disease-free. Then came the twist that makes this case report valuable to practicing hematologists. Rather than recurring locally in the same gland or spreading to distant lymph nodes, the lymphoma re-emerged as an isolated relapse in the contralateral thyroid lobe — the opposite side of the gland from the original tumor. Isolated late relapses of primary thyroid DLBCL are vanishingly rare; the review notes that relapsed or refractory disease in general, and central nervous system involvement in particular, are uncommon events in this patient population. The contralateral pattern raises intriguing questions about clonal biology: whether the relapse represented re-seeding from an occult residual clone within the gland or a truly independent second primary lymphoma arising in the same chronically inflamed tissue environment.

Treating a relapse six years after the original diagnosis posed a practical dilemma. Because the patient had already received anthracycline-based chemotherapy and rituximab, the team chose an off-label regimen abbreviated Pola-R-miniCHP. The key ingredient is polatuzumab vedotin, an antibody-drug conjugate that ferries a potent cytotoxic payload, monomethyl auristatin E, directly to CD79b, a component of the B-cell receptor complex expressed on malignant cells. Polatuzumab-based combinations have reshaped the landscape of relapsed and refractory DLBCL since demonstrating survival benefits in randomized testing, and the miniaturized chemotherapy backbone in this regimen was designed to reduce cumulative toxicity in an elderly patient. The gamble worked: the contralateral relapse again melted into complete remission, giving the patient two separate cures from the same rare disease across nearly a decade.

The literature review that accompanies the case report assembles the fragmented evidence base into a coherent picture. Reported five-year overall survival rates for primary thyroid DLBCL span a wide range, from 57 percent to 88 percent, reflecting heterogeneity in patient age, stage, histological subtype, and treatment era across the small published series. The better end of that spectrum approaches outcomes for early-stage DLBCL at more conventional nodal sites, underscoring that when the disease is caught while confined to the thyroid and treated promptly with modern immunochemotherapy, long-term survival is a realistic expectation. The authors also highlight that central nervous system relapse, a feared complication of aggressive DLBCL, appears infrequently in this population, which has implications for how aggressively clinicians need to pursue CNS-directed prophylaxis at diagnosis.

What the review cannot yet deliver is a definitive, evidence-based treatment guideline, and the authors are candid about why. The rarity of primary thyroid DLBCL means that every published series is small, retrospective, and vulnerable to selection bias. Randomized trials enrolling patients with this specific presentation are practically impossible to mount. Their proposed way forward is registry-based research, particularly studies that group primary extranodal DLBCLs of various origins together to achieve analyzable patient numbers while still capturing the distinctive features of thyroid disease. Such registries could clarify outstanding controversies, including the optimal role of radiotherapy consolidation, the necessity and duration of CNS prophylaxis, the value of molecular risk stratification, and how best to manage the rare relapses like the one documented in this report.

For the broader oncology community, the case carries several practical lessons. First, a rapidly enlarging thyroid mass with compressive or neurological symptoms in an older patient, especially one with background autoimmune thyroid disease, should prompt consideration of lymphoma alongside the more common carcinomas — because the diagnostic and therapeutic pathways diverge sharply, and inappropriate upfront surgery can delay the correct treatment. Second, adequate tissue via core needle or surgical biopsy is not a formality but the linchpin of accurate subtyping. Third, relapsed primary thyroid DLBCL, while exceptionally uncommon, may be amenable to the same novel agents that have improved salvage therapy for DLBCL elsewhere, as the successful off-label use of a polatuzumab-based regimen here demonstrates. The report thus functions as both a caution and an encouragement: vigilance at first presentation and flexibility at relapse can yield complete remissions even in a disease so rare that no guideline exists to follow.

The Hamburg authors, writing from one of Germany’s major university cancer centers, published their work open access so that clinicians encountering their own rare cases can consult the full analysis. As targeted immunotherapies continue to migrate from relapsed settings into frontline treatment across the lymphoma spectrum, the experience documented in this single patient may foreshadow how primary thyroid DLBCL is managed in the coming decade — with antibody-drug conjugates and other precision agents potentially joining or even replacing legacy regimens, and with international registries finally assembling enough patients to turn anecdote into evidence.

Subject of Research: Primary thyroid diffuse large B-cell lymphoma: diagnosis, treatment, and relapse management

Article Title: Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature

Article References: Kirkgöz, K., Weisel, K., Bokemeyer, C., & von Kroge, S. (2026). Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature. Annals of Hematology. https://doi.org/10.1007/s00277-026-07303-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07303-7

Keywords: primary thyroid lymphoma, diffuse large B-cell lymphoma, DLBCL, rituximab, R-CHOP, polatuzumab vedotin, thyroid cancer, non-Hodgkin lymphoma, relapse, chemoimmunotherapy, extranodal lymphoma, Annals of Hematology

The core problem CytoVI addresses is that antibody-based measurements are relative, not absolute. In flow cytometry, a protein’s signal depends on which fluorophore is attached to the antibody; in mass cytometry, on which heavy-metal isotope is used. Because laboratories choose different reporter molecules, staining protocols and antibody panels, the same cell type can look strikingly different across experiments. Batch effects arising from instrument performance, reagent lots and sample handling further obscure biology. Comparative studies across the vast public repositories of cytometry data have therefore been largely impractical, since different studies interrogate different marker sets with different technologies.

CytoVI is a variational autoencoder, a probabilistic latent variable model in which an encoder neural network compresses each cell’s protein expression profile into a low-dimensional latent vector that represents the cell’s intrinsic state, complete with an associated uncertainty. A decoder network then reconstructs the original protein expression from that embedding, conditioned on observed nuisance covariates such as batch, technology or antibody panel. By optimizing the evidence lower bound, a combination of a reconstruction term and a Kullback–Leibler regularization, the model learns embeddings that are corrected for technical variation while retaining biological signal. Depending on the expected heterogeneity of the sample, the latent space is assigned either an isotropic Gaussian prior or a more expressive mixture of Gaussians, which can optionally be informed by existing cell type labels in difficult integration scenarios.

Because the model is generative, it does far more than integrate. The trained decoder can produce batch-corrected expression estimates, test for differentially expressed proteins within a Bayesian framework, and, crucially, impute proteins that were never measured. When two experiments use partially overlapping antibody panels, the encoder reads only the shared backbone markers while the decoder reconstructs the union of all markers, effectively filling in the gaps with probabilistic estimates that carry explicit uncertainty. The same counterfactual decoding logic allows CytoVI to impute morphological features such as forward and side scatter into mass cytometry data, and even to impute transcriptomes into flow cytometry datasets when paired CITE-seq measurements are available as a reference.

The authors validated the model through a series of rigorous benchmarks. Posterior predictive checks showed that CytoVI faithfully reproduces the statistical properties of flow cytometry, mass cytometry and CITE-seq data. In integration tests on replicate peripheral blood mononuclear cell samples measured in different batches, CytoVI removed technical variation while preserving cell type structure, performing at least on par with state-of-the-art tools such as cyCombine, FastMNN and Harmony, and avoiding the residual batch effects those methods left in specific immune compartments. The model remained robust even when more than two-thirds of the markers in one batch were masked, and training stayed computationally manageable, taking under 35 minutes for one million cells on a single GPU.

To demonstrate the scale of insight the approach enables, the team assembled an integrated B cell maturation atlas from mass cytometry data spanning twelve partially overlapping antibody panels. By controlling for batch and imputing non-overlapping markers, CytoVI characterized 350 surface proteins across transitional, naive and memory B cell compartments. Trajectory modeling with diffusion maps and CellRank revealed the differentiation path from transitional B cells toward class-switched memory cells, and the model’s differential expression module pinpointed proteins associated with immunoglobulin class-switching, including CD62L, CD71 and CD100, molecules known to mediate lymph node migration, antigen specificity and B cell–T cell communication.

The clinical potential of the method became apparent in analyses of patient cohorts. In a study of lymph node T cell infiltrates from 63 patients with B cell non-Hodgkin lymphoma, profiled with two overlapping flow cytometry panels, CytoVI’s label-free differential-abundance analysis automatically identified disease-associated T cell states. It reproduced known findings, such as follicular helper T cell enrichment in follicular lymphoma, but also resolved a proliferating population as predominantly CD8-positive T cells and uncovered a small cluster of CD4/CD8 double-negative T cells enriched in diffuse large B cell lymphoma and mantle cell lymphoma that the original manual analysis had missed. By integrating the flow data with paired CITE-seq measurements, the team imputed transcriptomes and showed that these double-negative cells are in fact cytotoxic Vδ1 gamma-delta T cells, a population previously reported to be enriched in lymphoma patients.

Perhaps most strikingly, CytoVI was applied to routine diagnostic flow cytometry for chronic lymphocytic leukemia. Training a reference model on a small set of patients and controls, the researchers used transfer learning to map new, unseen diagnostic samples into the reference latent space without retraining. Automatically detected CLL cell frequencies correlated strongly with expert hematologist annotations, and the kappa-to-lambda light-chain ratio computed within the automatically classified cells captured the monoclonality that is a diagnostic hallmark of the disease. Combining these two features in a simple classifier distinguished CLL patients, including those with minimal residual disease, from controls with an area under the curve of about 0.74, a task that remains challenging even for experts.

The authors frame CytoVI as a step toward a model-centric view of cytometry, analogous to the shift already underway in single-cell transcriptomics. Because cytometry is destructive and restricted to predefined panels, proteins absent from an original experiment are normally lost forever; CytoVI’s probabilistic imputation breathes new life into archived datasets and could support community-scale protein atlases built from conventional assays. With intrinsic uncertainty estimates suited to privacy-sensitive clinical deployment, interoperability with Scanpy workflows, and the ability to fuse the scale of cytometry with the molecular resolution of single-cell genomics, the model lays groundwork for AI-powered cytometry that could accelerate biomarker discovery, standardize diagnostic interpretation and systematically chart cellular states across health and disease.

Subject of Research: Deep generative modeling for unified analysis of antibody-based single-cell data

Article Title: CytoVI: deep generative modeling of antibody-based single cell data

Article References: Ingelfinger, F., Levy, N., Ergen, C., Bakulin, A., Becker, A., Boyeau, P., Kim, M., Ditz, D., Dirks, J., Maaskola, J., Wertheimer, T., Zeiser, R., Widmer, C. C., Amit, I., & Yosef, N. (2026). CytoVI: deep generative modeling of antibody-based single cell data. Nature Methods, 23(10), 2054-2065. https://doi.org/10.1038/s41592-026-03224-5

Image Credits: AI Generated

DOI: 10.1038/s41592-026-03224-5

Keywords: CytoVI, flow cytometry, mass cytometry, CITE-seq, deep generative model, variational autoencoder, batch correction, protein imputation, B cell atlas, non-Hodgkin lymphoma, chronic lymphocytic leukemia, scvi-tools

The scale of the problem that motivated the study is considerable. According to the 2022 GLOBOCAN report, non-Hodgkin lymphoma ranks as the tenth most common cancer worldwide and the eleventh leading cause of cancer death, striking males more often than females. But the geographic distribution of the pediatric burden is strikingly skewed: roughly 84 percent of cases in children under 16 occur in Latin America, Africa, Asia, the Caribbean, and Polynesia, and an estimated 80 percent of children who develop these tumors live in developing countries. In Ghana specifically, non-Hodgkin lymphoma is the third leading cause of childhood cancer death and accounts for about 7 percent of childhood neoplasms. A three-year review at Korle Bu Teaching Hospital found that lymphomas made up over 60 percent of childhood malignancies, with Burkitt lymphoma the most common type.

Diagnosing and classifying these tumors accurately is far harder than it might seem. The World Health Organization recognizes more than 50 subtypes of non-Hodgkin lymphoma, distinguished by clinical presentation, tumor cell morphology, antigenic marker expression, and genetic features. Morphology alone—the appearance of cells under a microscope after standard hematoxylin and eosin staining—is often insufficient, because many subtypes closely resemble one another. The WHO explicitly warns that morphological assessment by itself risks discordant reports even among experienced pathologists, complicating the identification of rare and heterogeneous cases and hindering the planning of targeted therapy. In well-resourced health systems, immunophenotypic testing, cytogenetics, and molecular assays are routinely folded into the diagnostic workup, and there is solid evidence that this integration improves clinical outcomes and overall survival. In Ghana and much of Africa, however, treatment typically proceeds on the basis of clinical and histological information alone, because laboratories lack equipment, reagents are costly, and trained personnel are scarce.

The consequence, the researchers note, is that many children may be treated without a definitive pathological diagnosis—either undertreated, or given unnecessarily high doses of chemotherapy that are toxic and harmful. Against this backdrop, the team set out to evaluate the immunophenotypic characteristics of three non-Hodgkin lymphoma subtypes and the survival outcomes of the children bearing them, using three markers with distinct biological roles: CD3, which broadly marks T lymphocytes and helps establish tumor cell lineage; CD25, the interleukin-2 receptor alpha chain, which reflects host immune response within the tumor microenvironment; and BCL-2, a protein that blocks programmed cell death and is associated with resistance to apoptosis and chemotherapy.

The methodology was meticulous given the constraints. The team retrieved formalin-fixed, paraffin-embedded tissue blocks from the hospital’s pathology archives, identifying 133 cases of children under 18 who were clinically diagnosed with non-Hodgkin lymphoma between 2018 and 2022. Children with incomplete data, inadequate tissue, or HIV co-infection were excluded. Thin sections cut from each block were stained with hematoxylin and eosin, and two independent pathologists at the Kwame Nkrumah University of Science and Technology reviewed every slide while blinded to previous reports; any disagreement was adjudicated by a third pathologist. Of the initial 133 cases, 38 were confirmed as showing the histomorphological features of non-Hodgkin lymphoma—diffuse effacement of normal nodal architecture, atypical lymphoid proliferation, increased mitotic activity, and loss of normal germinal center structures—and were suitable for immunohistochemistry.

For the immunohistochemical analysis, serial sections underwent heat-induced epitope retrieval in citrate buffer, blocking of endogenous peroxidase and non-specific protein binding, and staining with mouse monoclonal antibodies against CD3, CD25, and BCL-2. Signal was detected with an enzyme-conjugated secondary antibody and a chromogenic substrate, producing brown staining visible under a light microscope. Known positive control tissues—tonsil for CD3 and reactive lymph node for BCL-2 and CD25—accompanied each staining batch, while negative controls omitted the primary antibody. Two pathologists independently scored both staining intensity, on a scale from zero to strong, and the proportion of tumor cells stained, from under 20 percent to over 80 percent, with a third pathologist resolving discrepancies. Combined scores ranked each case as showing no, low, moderate, or high expression.

The results revealed a distinctly heterogeneous immunophenotypic landscape. BCL-2 was the most frequently expressed marker, present in 55.3 percent of cases, followed by CD3 in 36.8 percent, while CD25 was expressed in only 5.3 percent of patients. Co-expression occurred at varying levels, with 28.9 percent of cases expressing both BCL-2 and CD3, and 5.3 percent expressing all three markers simultaneously. Stratifying expression by clinical aggressiveness added nuance: BCL-2 showed high expression in 76.9 percent of low-grade cases, moderate expression in half of high-grade cases, and low expression in 36.4 percent of Burkitt lymphomas. Notably, although Burkitt lymphoma is classically characterized by absent or low BCL-2 expression, a substantial subset of the Burkitt cases in this cohort were positive—consistent with emerging evidence from other studies, including reports of BCL-2 positivity in roughly 23 percent of Burkitt lymphoma cases in European and adult series, which challenges the diagnostic utility of this marker and underscores the biological heterogeneity of these tumors.

The survival data were sobering. Of the 38 participants, 21 had complete follow-up data for survival analysis. Median overall survival from diagnosis was 22 months, with survival rates of 76 percent at 10 months, 61 percent at 20 months, 40 percent at 30 months, and 20 percent at 40 months—a steep and steady decline. The clinical outcomes were equally stark: 30.6 percent of patients died while on admission for chemotherapy, 27.8 percent abandoned treatment, 2.8 percent died shortly after discharge, and only 38.8 percent survived and were discharged. When the researchers used log-rank tests to identify factors associated with survival, age, gender, duration of symptoms, CD3 expression, CD25 expression, and clinical aggressiveness showed no significant association. But BCL-2 expression was significantly linked to inferior survival (p = 0.030)—patients expressing the marker had a median survival of 12 months versus 30 months for those who did not—and nodal or extranodal involvement was even more strongly associated (p < 0.001). This aligns with the biology: BCL-2 proteins downregulate apoptosis and promote chemoresistance, while spread to multiple nodal and extranodal sites signals advanced, aggressive disease, a principle embedded in the staging systems used for pediatric lymphoma.

The study’s limitations temper its conclusions, and the authors are candid about them. Poor archiving systems meant many tissue blocks could not be retrieved, shrinking the sample and limiting statistical power—the cohort was underpowered for multivariable Cox proportional hazards modeling, so survival findings warrant caution. The retrospective design prevented standardization of chemotherapy and clinical care, and survivors were not followed long-term. Because no B-cell lineage markers such as CD20, MYC, CD10, BCL6, or Ki-67 were included, the lineage of CD3-negative tumors could not be definitively determined, and CD3 positivity alone cannot distinguish neoplastic T cells from background reactive infiltrates—meaning the apparent proportion of T-cell lymphomas should be interpreted cautiously, even though it was higher than previously reported in Ghana. Cases were also grouped by clinical aggressiveness rather than formal WHO classification. Yet the core message stands: in a setting where most children present with advanced disease, treatment abandonment is common, and advanced immunophenotypic stratification is unavailable, simple and affordable biomarker panels like the one tested here could offer a practical first step toward effective patient stratification and, ultimately, better survival outcomes for children with non-Hodgkin lymphoma in Ghana and similar resource-limited settings.

Subject of Research: Immunophenotypic biomarker expression and survival outcomes in childhood non-Hodgkin lymphoma in Ghana

Article Title: Assessment of Selected Immunophenotypic Markers in Childhood Non‐Hodgkin's Lymphomas in Ghana: A Possible Tool for Effective Stratification of Patients and Assessment of Survival Outcomes

Article References: Assessment of Selected Immunophenotypic Markers in Childhood Non‐Hodgkin's Lymphomas in Ghana: A Possible Tool for Effective Stratification of Patients and Assessment of Survival Outcomes. (n.d.). https://doi.org/10.1002/cnr2.70711

Image Credits: AI Generated

DOI: 10.1002/cnr2.70711

Keywords: non-Hodgkin lymphoma, pediatric oncology, Ghana, BCL-2, CD3, CD25, immunohistochemistry, survival analysis, Burkitt lymphoma, resource-limited settings, biomarkers, treatment abandonment

The study, led by Gretchen A. McNally and Grace Ji-eun Shin of The Ohio State University Comprehensive Cancer Center, tracked 25 adults with non-Hodgkin lymphoma who were beginning first-line chemotherapy with vincristine-containing CHOP or EPOCH regimens. Rather than conducting an artificial clinical-trial setting, the researchers embedded their measurements directly into routine care, drawing blood and administering questionnaires at the same visits where patients received their infusions. Sixteen participants received CHOP, typically delivered in an outpatient infusion lasting about ninety minutes, while nine received EPOCH, which required roughly five days of inpatient admission with continuous drug infusion over 96 hours. The team followed participants through four to six months of chemotherapy, and a small subset of six survivors for an additional 24 to 42 months after treatment ended.

The centerpiece of the research is neurofilament light chain, or NfL, a structural protein that forms part of the internal scaffolding of nerve axons. When axons are injured, NfL leaks into the surrounding fluid and eventually reaches the bloodstream, where it can be quantified with single-molecule array technology capable of detecting concentrations as low as 0.038 picograms per milliliter. Because NfL rises after virtually any form of neuroaxonal damage, from multiple sclerosis to traumatic brain injury, its interpretation requires careful longitudinal context. In the case of vincristine, the biological logic is compelling: the drug disrupts microtubule assembly and axonal transport, the cellular freight system that keeps long peripheral nerves alive, and the resulting distal axonal injury should release NfL into circulation.

That prediction was borne out dramatically. Using mixed-effects statistical models on log-transformed data, the researchers found that model-estimated plasma NfL rose from a geometric mean of 26.3 picograms per milliliter before the first chemotherapy cycle to 91.6 picograms per milliliter before the second cycle, 107.2 before the fourth, and 94.3 before the sixth. Relative to the pretreatment measurement, these values represent increases of roughly 248 to 307 percent, with every timepoint reaching statistical significance at p less than 0.001. Notably, the rise was not a simple cumulative-dose curve of the kind reported for platinum drugs or paclitaxel; instead, NfL surged early and then plateaued at a sustained elevation, a pattern consistent with prior clinical observations that vincristine neuropathy does not track neatly with total cumulative dose.

Alongside the biomarker measurements, patients completed the EORTC QLQ-CIPN20 questionnaire, a validated 20-item instrument capturing sensory, motor, and autonomic neuropathy symptoms, as well as the Brief Pain Inventory Short Form for pain severity. Clinicians recorded neuropathy grades using the National Cancer Institute’s Common Terminology Criteria for Adverse Events as part of standard toxicity documentation. Patient-reported symptom scores climbed significantly during treatment, with the model-estimated CIPN20 score rising 23.4 percent by the time of the sixth cycle compared with baseline. Clinician-graded CTCAE neuropathy also increased, with grade 1 or higher neuropathy documented in a third of participants by the final on-treatment assessment, though the clinician-recorded changes were smaller and less clearly longitudinal than what patients reported about themselves.

The relationship between the blood biomarker and the lived experience of neuropathy proved more nuanced than a simple one-to-one correspondence. When the researchers pooled all paired NfL and CIPN20 observations across treatment visits, they found a modest but statistically significant association, with a repeated-measures correlation of 0.439 and a p value of 0.020 across 51 paired observations. However, at any single timepoint, the two measures did not correlate reliably, and exploratory lagged analyses of whether early NfL change predicted later symptom worsening were inconclusive in the full dataset. A post hoc sensitivity analysis, excluding one participant with extreme symptom severity, hinted that early NfL concentrations might anticipate later patient-reported symptoms, but the authors are careful to frame this as hypothesis-generating rather than proof of predictive value.

This imperfect alignment between biology and symptom is not a failure of the biomarker; it is a window into the complexity of chemotherapy neurotoxicity. Patient-perceived symptoms may emerge before, during, or after detectable NfL release, reflecting not just structural axonal injury but also altered nerve excitability, immune activation, pain sensitization, and functional adaptation. Emerging mechanistic research suggests that NfL itself may not be a passive bystander: a recent study reported that NfL released after neuronal damage can activate myeloid immune cells and promote neuroinflammation, and preclinical work has implicated astrocyte activation, macrophage infiltration, cytokine release, and NLRP3 inflammasome signaling in vincristine-induced pain. NfL may therefore be best understood as one node in a broader injury-and-immune response rather than a same-day readout of symptom severity.

The study also illuminated the messy realities of real-world oncology that biomarker research must eventually confront. A quarter of participants, six of 25, underwent vincristine dose modifications, including reductions, holds, or discontinuations, for reasons ranging from neuropathy to ileus and constipation. Dose-modified participants showed a numerically larger median rise in NfL, approximately 4.3-fold versus 1.75-fold, but paradoxically reported no median increase in CIPN20 scores, while non-modified participants reported a median increase of six points. These exploratory comparisons did not reach statistical significance, but they suggest that clinical decisions to reduce drug exposure reshape both the biology and the symptom trajectory in ways that any future predictive model must account for. Among the six survivors followed two to three and a half years after treatment, patient-reported neuropathy scores remained elevated, ranging from 20 to 36, and the two participants with the highest long-term symptom burden had also experienced dose modification during therapy.

The authors are candid about the limitations of their pilot. Twenty-five participants from a single center constitute a small cohort with substantial missing data, heterogeneous early sampling because some patients were recruited after treatment had already begun, and no standardized neurologic examination, nerve conduction studies, or quantitative sensory testing to validate the biomarker against objective nerve function. NfL concentrations are also influenced by age, kidney function, body size, and neurological comorbidities, all of which complicate interpretation in a small and demographically diverse sample. The clinician-recorded CTCAE grades came from routine care rather than a standardized assessment protocol, introducing provider-level variability. These constraints mean the study cannot establish NfL as a standalone diagnostic or predictive tool, and the authors explicitly caution that larger studies with standardized pretreatment sampling are needed before NfL can inform routine clinical decisions.

What the study does establish is a methodological foundation and a compelling proof of concept. All prespecified feasibility criteria were met: every enrolled participant contributed early assessment data, retention through the final on-treatment timepoint reached 100 percent among those who remained eligible, and the full sampling schedule fit within the six-month treatment window. Plasma NfL proved sensitive to vincristine exposure, rising early and staying elevated, while patient-reported symptoms rose in parallel without perfectly mirroring the biomarker. The most productive path forward, the researchers argue, is not to replace patient questionnaires or clinician grading with a blood test, but to combine all three into a multimodal monitoring framework in which NfL provides biological context that symptoms alone cannot supply. For a growing population of lymphoma survivors facing persistent neuropathy with few treatment options, the prospect of identifying nerve injury early, before symptoms become disabling, represents a meaningful step toward personalized neuroprotection during cancer therapy.

Subject of Research: Neurofilament light chain as a blood biomarker of vincristine-induced peripheral neuropathy in lymphoma chemotherapy

Article Title: Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study

Article References: McNally, G. A., Shin, G. J.-E., Worthen-Chaudhari, L., Schnell, P. M., Flora, L., Krishna, S. S., Voorhees, T., Baiocchi, R., Bond, D., Christian, B., Maddocks, K., Sawalha, Y., & Lustberg, M. B. (2026). Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study. Journal of Neurology, 273(10), Article 594. https://doi.org/10.1007/s00415-026-14096-2

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14096-2

Keywords: neurofilament light chain, chemotherapy-induced peripheral neuropathy, vincristine, non-Hodgkin lymphoma, biomarker, patient-reported outcomes, CHOP, EPOCH, neuroaxonal injury, survivorship, CTCAE, longitudinal cohort study

The answer, according to the analysis, is a carefully qualified yes. Researchers led by Iftikhar Khan and colleagues conducted a PRISMA-guided search of PubMed, Embase, and the Cochrane Library through May 2025, identifying randomized controlled trials that compared R² against rituximab monotherapy, chemoimmunotherapy, or lenalidomide alone. Four trials encompassing 1,315 patients made the final cut. The primary endpoints were the overall response rate, complete response, and partial response, while secondary outcomes included two-year progression-free survival, three-year overall survival, and adverse events. The results paint a picture of a regimen that is broadly equivalent to its competitors, but with important caveats that clinicians and patients alike will need to weigh.

On the headline efficacy measures, the two approaches were remarkably close. The relative risk for overall response with R² was 1.09, for complete response 1.06, and for partial response 1.19, none of which reached statistical significance. Three-year overall survival was essentially identical between the groups, with a relative risk of 1.00. In other words, patients receiving the doublet were just as likely to see their disease shrink and just as likely to be alive three years later as those on standard regimens. For a therapy that spares patients the toxicities of cytotoxic chemotherapy, that equivalence alone carries real clinical weight.

Progression-free survival, however, told a more complicated story. In the primary analysis, R² did not differ significantly from comparators at the two-year mark, with a relative risk of 1.53 and a confidence interval spanning 0.51 to 4.54, and a P value of 0.236. More troubling for the statistical integrity of that estimate was the heterogeneity statistic: an I² of 85.3 percent, indicating that the included trials varied so widely that pooling them produced an unstable result. High heterogeneity in a meta-analysis is a warning sign that the studies being combined may differ in populations, comparators, or design in ways that make a single summary estimate unreliable.

The researchers therefore ran a sensitivity analysis, excluding the largest trial, RELEVANCE, which contributed roughly half of the pooled population and was the only study comparing R² directly against chemoimmunotherapy. With RELEVANCE removed, a progression-free survival benefit for R² suddenly emerged, with a relative risk of 2.05, a confidence interval of 1.18 to 3.55, a P value of 0.038, and heterogeneity collapsing to zero. But this finding demands cautious interpretation. When a benefit appears only after deleting the biggest trial, the honest conclusion is that the evidence base is divided rather than decisive. The authors themselves conclude that R² represents a viable chemotherapy-free option rather than a demonstrably superior one, a distinction that matters enormously for treatment decisions.

Safety data from the analysis add further texture to the picture. Skin reactions were nearly three times more frequent with R², with a relative risk of 2.76 and a P value of 0.043, and diarrhea was roughly twice as common, with a relative risk of 1.98 and a P value of 0.004. These are the signature toxicities of lenalidomide, an oral agent that modulates the immune system through mechanisms that include altering cytokine production and stimulating T and natural killer cells. Encouragingly, severe hematologic toxicities, the dangerous drops in blood counts that drive many chemotherapy complications, were not significantly different between the groups, reinforcing the characterization of R² as having a manageable, predominantly non-hematologic toxicity profile.

The biological rationale behind the combination is what makes it scientifically compelling. Rituximab is a monoclonal antibody that binds CD20 on B cells, recruiting the immune system to destroy the cancer cells directly. Lenalidomide works differently, reshaping the tumor microenvironment and enhancing immune surveillance. Combining a targeted antibody with an immune-modulating small molecule is precisely the kind of rational pairing that has transformed treatment across hematology, and the follicular lymphoma data suggest the concept translates into real clinical activity without the collateral damage of cytotoxic drugs.

Yet the limitations of the evidence base are impossible to ignore. Four trials and 1,315 patients is a modest foundation for practice-changing conclusions, and the trials compared R² against three different kinds of comparators, from antibody monotherapy to full chemoimmunotherapy. That diversity is almost certainly the source of the extreme heterogeneity observed in the primary analysis. The authors call for longer-term randomized data with standardized comparators, and that request is well founded: without head-to-head trials using consistent control arms and extended follow-up, the field cannot determine whether R² merely matches standard care or, in selected populations, exceeds it.

For patients, the practical takeaway is one of options rather than revolution. Follicular lymphoma’s relapsing course means that treatment choices are rarely one-shot decisions; patients typically cycle through multiple lines of therapy over years or decades. A regimen that delivers response rates and survival comparable to chemoimmunotherapy while avoiding chemotherapy’s cumulative toxicity offers a meaningful alternative, particularly for older patients, those with comorbidities, or anyone prioritizing quality of life during long periods of disease control. The increased risk of skin reactions and diarrhea is real but generally manageable with dose adjustments and supportive care.

The study, which received no external funding and declared no competing interests, arrives at a moment when chemotherapy-free approaches are reshaping lymphoma care more broadly. As immunotherapies and targeted agents multiply, the central question in indolent lymphomas is shifting from whether we can treat the disease to how we can treat it with the least harm. This meta-analysis does not crown R² as a new standard, but it firmly establishes the doublet as a legitimate contender, backed by randomized evidence, and sets a clear agenda for the trials that must now follow to resolve the survival question the current data leave open.

Subject of Research: Efficacy of rituximab plus lenalidomide combination therapy compared with standard regimens in follicular lymphoma

Article Title: Efficacy of rituximab plus lenalidomide regimens in follicular lymphoma: a meta-analysis of randomized controlled trials

Article References: Khan, I., Habib, H., Butt, A. I., Hafeez, A. S., Mubarika, M., Alokozay, E., Shaharyar, M., Aleem, S., Alam, U., Shadab, H. A., Naeem, A. B., Nouman, M., Haris, H. M., Dogar, F. N., Fatima, Z. M., Azhar, M. J., Khan, S., Imtiaz, A., Malik, S. J., … Khan, A. (2026). Efficacy of rituximab plus lenalidomide regimens in follicular lymphoma: a meta-analysis of randomized controlled trials. Annals of Hematology. https://doi.org/10.1007/s00277-026-07248-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07248-x

Keywords: follicular lymphoma, rituximab, lenalidomide, meta-analysis, randomized controlled trials, chemoimmunotherapy, progression-free survival, non-Hodgkin lymphoma, immunomodulatory therapy, adverse events, hematology, cancer treatment

The research, published in BMC Cancer, was conducted by a team based at Shahid Sadoughi University of Medical Sciences in Yazd and collaborating institutions, using records from the Iranian National Cancer Registry. The team analyzed 4,928 cases of Hodgkin lymphoma and 13,600 cases of non-Hodgkin lymphoma diagnosed over the four-year study window. To make the numbers comparable across years and populations, the researchers calculated age-standardized incidence rates, a statistical adjustment that accounts for differences in the age structure of the population, using the World Health Organization’s standard population as the reference. This adjustment matters because a country with a young population can show fewer raw cancer counts simply because fewer people have reached the ages at which cancer risk climbs steeply.

For Hodgkin lymphoma, a disease that typically originates in B lymphocytes and is strongly associated with Epstein-Barr virus infection in many regions, the age-standardized incidence rate rose from 1.4 per 100,000 people in 2014 to 1.59 per 100,000 in 2017. That may sound like a small shift, but in epidemiological terms a steady climb of this magnitude over just four years signals a genuine trend rather than random year-to-year fluctuation, particularly when the same direction of change appears across demographic subgroups. The rates were not distributed evenly across the country. Yazd province recorded the highest Hodgkin lymphoma rate in 2014 at 2.74 per 100,000, while Lorestan topped the national figures in 2017 at 2.50 per 100,000, both well above the national average.

Sex-based differences emerged clearly in the data. Among Iranian men, the age-standardized incidence of Hodgkin lymphoma climbed from 1.66 per 100,000 in 2014 to 1.89 per 100,000 in 2017, while among women the corresponding figures rose from 1.13 to 1.29 per 100,000. In other words, men carried roughly a fifty percent higher burden of the disease than women throughout the study period, a gap consistent with patterns reported in many other populations and one that researchers attribute to a complex interplay of hormonal, immunological, and environmental factors. The parallel rise in both sexes suggests that whatever is driving the overall increase operates broadly rather than within one group alone.

Non-Hodgkin lymphoma, which encompasses a large and heterogeneous family of B-cell and T-cell malignancies, showed both a higher baseline and a similar upward trajectory. The age-standardized incidence rate increased from 4.26 per 100,000 in 2014 to 4.54 per 100,000 in 2017, meaning that non-Hodgkin lymphoma struck Iranians at roughly three times the rate of its Hodgkin counterpart. The provincial extremes were striking: Yazd again recorded the highest rate in 2014 at 7.13 per 100,000, and Ilam province reached 8.13 per 100,000 in 2017, figures that approach levels seen in some high-income countries. As with Hodgkin lymphoma, men were disproportionately affected, with rates rising from 5.29 to 5.52 per 100,000 over the study period, compared with a range of 3.26 to 3.58 per 100,000 among women.

What sets this study apart from routine registry reports is its use of spatial analysis, a set of techniques borrowed from geography that ask whether disease cases are scattered randomly across a map or whether they cluster in ways that hint at shared environmental or social causes. The researchers employed geographic information system tools and computed Moran’s Index, a formal statistical measure of spatial autocorrelation in which values near zero indicate randomness and positive values indicate that neighboring areas tend to share similar disease rates. For Hodgkin lymphoma, the analysis detected statistically significant geographic clustering in 2014, with a Moran’s Index of 0.12 and a p-value of 0.05, and again in 2015, with an index of 0.14 and a p-value of 0.03. Intriguingly, this clustering dissolved in 2016 and 2017, suggesting that the geographic pattern of the disease was itself shifting during the study years.

For non-Hodgkin lymphoma, the spatial story was different. In most years the cases showed no significant clustering, but 2016 stood out with clear and highly significant geographic aggregation, marked by a Moran’s Index of 0.18 and a p-value below 0.001. A transient clustering pattern like this is exactly the kind of signal that motivates further investigation: it could reflect a localized environmental exposure, an outbreak of an infection known to trigger lymphoproliferative disease, changes in diagnostic practice concentrated in certain provinces, or simply variation in how completely the registry captured cases from different regions. The authors are careful not to overinterpret the pattern, but they emphasize that such geographic heterogeneity deserves systematic follow-up.

The rising trend itself invites several possible explanations, none of which can be confirmed from registry data alone. Improvements in diagnostic imaging, pathology services, and cancer registration could account for part of the increase, as better detection inevitably raises recorded incidence. Yet the consistency of the trend across both lymphoma types and both sexes over a short period keeps open the possibility of true changes in disease frequency. Internationally, non-Hodgkin lymphoma incidence has been linked to factors ranging from viral infections such as Epstein-Barr virus and HIV to immunosuppression, autoimmune conditions, pesticide exposure, and aging populations. Iran’s distinct regional patterns, with provinces such as Yazd, Lorestan, and Ilam repeatedly exceeding national averages, provide natural starting points for studies that could test environmental and infectious hypotheses directly.

The study’s authors describe lymphoma in Iran as a silent public health concern, a phrase that captures the way these malignancies accumulate burden without attracting the attention devoted to more common cancers. Their conclusion is a call for targeted public health interventions, particularly in the provinces where incidence runs highest, and for further research to clarify the risk factors underlying the geographic and demographic disparities the registry data reveal. Because the analysis rests on de-identified registry records and was approved by an institutional ethics committee, it demonstrates how routinely collected national health data, when combined with spatial statistics, can generate actionable intelligence at relatively low cost.

For the international cancer research community, the Iranian findings add a valuable data point from a Middle Eastern population whose lymphoma epidemiology has been less thoroughly documented than that of Europe or North America. The combination of rising age-standardized rates, a persistent male excess, and province-level hotspots paints a picture of a disease landscape in transition. Whether the upward slope of 2014 through 2017 has continued in the years since, and whether the fleeting clusters of 2015 and 2016 reappear in later data, are questions that only sustained registry investment can answer. What is already clear is that lymphoma in Iran is neither rare nor randomly distributed, and that the tools now exist to find it wherever it concentrates.

Subject of Research: Epidemiology and geographic clustering of Hodgkin and non-Hodgkin lymphoma in Iran based on national cancer registry data

Article Title: Epidemiology of hodgkin and non-Hodgkin lymphomas in Iran: shedding light on a silent public health concern

Article References: Ghafouri, A. H., Rahmanian, V., Hosseini, S., Hosseini, S. M. H., & Hazar, N. (2026). Epidemiology of hodgkin and non-Hodgkin lymphomas in Iran: shedding light on a silent public health concern. BMC Cancer. https://doi.org/10.1186/s12885-026-17101-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17101-z

Keywords: Hodgkin lymphoma, non-Hodgkin lymphoma, Iran, cancer epidemiology, age-standardized incidence rate, National Cancer Registry, spatial analysis, Moran's Index, GIS, public health, Epstein-Barr virus, geographic clustering

Diffuse large B-cell lymphoma, or DLBCL, is the most frequent subtype of non-Hodgkin lymphoma, accounting for approximately 30 to 40 percent of all cases. For two decades, the frontline standard of care was R-CHOP, a five-drug immunochemotherapy combining the monoclonal antibody rituximab with three chemotherapeutic agents and a corticosteroid. Despite countless attempts to improve upon it with novel agents, R-CHOP remained essentially unchallenged until the POLARIX trial demonstrated that swapping vincristine for polatuzumab vedotin—a targeted antibody-drug conjugate directed against CD79b, a signaling component of the B-cell receptor—produced significantly superior outcomes. That result transformed Pola-R-CHP into the new global standard for previously untreated DLBCL, and the regimen was approved in China in April 2023 for adult patients.

Yet the POLARIX trial enrolled only patients with international prognostic index scores of 2 through 5, meaning patients considered to have intermediate or high-risk disease. The IPI is a well-established scoring system that predicts prognosis in DLBCL using five factors: age, tumor stage, number of extranodal sites involved, performance status, and serum lactate dehydrogenase levels. Patients scoring 0 or 1 are conventionally labeled low-risk and represent approximately 30 percent of newly diagnosed cases. Because they were excluded from the pivotal trial, this substantial population became a critical evidence gap. The problem is compounded by the fact that low IPI scores do not guarantee biological simplicity. Many of these patients carry molecular and pathological features known to undermine standard therapy, including bulky tumors, double-expressor lymphoma, and abnormalities of the TP53 gene, the so-called guardian of the genome.

The new study, led by Yuhong Ren and Peng Liu of Zhongshan Hospital, Fudan University, together with colleagues across China, set out to fill that gap using real-world data. Between June 2023 and July 2025, the researchers enrolled 118 consecutive previously untreated DLBCL patients with IPI scores of 0 or 1 who received at least one cycle of Pola-R-CHP. The median age was 53.5 years, with patients ranging from 17 to 87 years old. Despite their formally low-risk classification, the cohort was biologically heterogeneous and carried a surprising burden of adverse features: 51.7 percent had the non-germinal center B-cell-like subtype, 24.6 percent had double-expressor lymphoma, 9.3 percent had double-hit or triple-hit lymphoma, 25.4 percent showed high P53 expression, 12.7 percent had bulky disease, and 62.7 percent had extranodal involvement.

The treatment protocol followed a well-defined structure. Each 21-day cycle comprised polatuzumab vedotin at 1.8 milligrams per kilogram of body weight, rituximab at 375 milligrams per square meter, cyclophosphamide at 750 milligrams per square meter, doxorubicin at 50 milligrams per square meter or epirubicin at 70 milligrams per square meter, and prednisone at 100 milligrams orally for five consecutive days. Patients received a median of six cycles. Efficacy was assessed using whole-body fluorodeoxyglucose PET/CT or contrast-enhanced CT imaging after three to four cycles and again at the end of treatment, with responses graded according to the 2014 Lugano classification, the international standard for lymphoma response assessment.

The results were remarkable. Among the 68 patients who had completed end-of-treatment evaluation at the data cut-off of August 2025, 63 achieved a complete response, yielding a complete response rate of 92.6 percent. The overall response rate reached 98.5 percent at end of treatment and 98.9 percent at interim assessment, with 78.2 percent of interim-evaluated patients already in complete remission after just three to four cycles. Only two patients experienced disease progression during follow-up, both of whom had central nervous system involvement, and no deaths occurred at a median follow-up of 7.1 months. Importantly, the 50 patients without end-of-treatment assessment had not progressed, died, or been lost to follow-up; they were simply still undergoing treatment or awaiting imaging, meaning the missing data reflected short follow-up rather than treatment failure.

Perhaps most striking was the consistency of responses across molecular subgroups. Exploratory analyses showed broadly similar response rates at both interim and end-of-treatment time points among elderly patients, those with the non-germinal center subtype, extranodal disease, double-expressor lymphoma, and double-hit or triple-hit lymphoma. The one exception was the high P53 expression subgroup, where the complete response rate was numerically lower at 78.6 percent compared with 96.9 percent in patients with low or absent P53 expression. This finding aligns with the well-documented biology of TP53 alterations, which are associated with genomic instability and chemoresistance in lymphoma. However, the researchers caution that the small number of evaluable patients in this subgroup prevents definitive conclusions, and they suggest that the bystander effect of antibody-drug conjugates—the ability of the drug payload to diffuse into neighboring tumor cells that may not express the target antigen—could theoretically help overcome the clonal heterogeneity that drives resistance.

Safety data from all 118 patients showed a tolerable profile without unexpected toxicity compared with the POLARIX trial. Any grade 3 or 4 adverse event occurred in 24.6 percent of patients. The most common adverse events overall were anemia in 68.6 percent, leukopenia in 47.5 percent, and decreased neutrophil count in 39.8 percent, the vast majority of which were mild to moderate. The most frequent severe toxicity was neutropenia, affecting 21.2 percent of patients at grade 3 or 4—a manageable side effect routinely addressed with dose adjustments and growth factor support in clinical practice. No new safety signals emerged, reinforcing the regimen’s established risk-benefit profile in a broader and more diverse population than the original trial captured.

The study’s authors place their findings in context by comparing them with other real-world cohorts and historical R-CHOP data. Published complete response rates for frontline Pola-R-CHP and R-CHOP in low-risk patients range from 80.6 to 96.5 percent, and the current results sit comfortably at the upper end of that spectrum. Notably, the Chinese cohort carried a heavier burden of adverse features than a comparable R-CHOP cohort from a Chinese phase 3 trial, with higher rates of impaired performance status, advanced stage disease, and double-expressor lymphoma, yet still achieved outstanding responses. The researchers acknowledge the inherent limitations of a retrospective, single-arm design conducted exclusively in China, including potential selection bias and immature survival data, and they emphasize that a conservative sensitivity analysis counting all unevaluated patients as non-responders still yielded a complete response rate of 85.1 percent.

The implications reach beyond the numbers. Roughly a third of DLBCL patients worldwide fall into the IPI 0-1 category, yet they remain underrepresented in clinical trials and continue to experience late relapses even in limited-stage disease, a pattern that contrasts with the survival plateau seen in advanced-stage patients. This study provides the first multicenter real-world evidence that Pola-R-CHP is both effective and tolerable in this population, even when adverse biological features are present. The authors call for prospective randomized trials to precisely define the magnitude of benefit, and for molecular subtyping strategies to better identify which low-risk patients harbor hidden resistance mechanisms. For now, the message for clinicians is clear: the antibody-drug conjugate revolution in lymphoma treatment appears to extend to nearly every patient who walks through the door, not just those who fit the narrow criteria of a registration trial.

Subject of Research: Frontline Pola-R-CHP treatment of low-risk diffuse large B-cell lymphoma

Article Title: Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China

Article References: Ren, Y., Liu, J., Lin, Z., Shou, L., Zeng, H., Wu, D., Zeng, Z., Zhou, F., Bao, L., Jing, H., Jiang, S., Liu, H., Shen, J., Yu, W., Zhou, H., Xu, J., Zhang, Y., Wang, T., Huang, H., … Liu, P. (2026). Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China. Clinical Cancer Bulletin, 5(1), Article 21. https://doi.org/10.1007/s44272-026-00073-3

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00073-3

Keywords: diffuse large B-cell lymphoma, Pola-R-CHP, polatuzumab vedotin, antibody-drug conjugate, international prognostic index, real-world study, R-CHOP, double-expressor lymphoma, TP53, complete response, non-Hodgkin lymphoma, immunochemotherapy